CLEARWATER, Fla.--(EON: Enhanced Online News)--Bovie Medical Corporation (NYSE MKT:BVX) today reaffirmed its outlook for 2017.
The Company confirmed its outlook that full year 2017 is expected to be another period of significant revenue growth, comprised of consistent performance in its core and OEM product lines, accelerated growth in J-Plasma® sales from its multi-specialty strategy, and new product additions to its growth product category. The Company also noted that it continues to be in a strong position to leverage its existing infrastructure and should see operating expenses, including R&D, continue to progressively decline as a percent of revenue as it moves forward into 2017.
Bovie Medical will host a conference call to review its fourth quarter and full year 2016 results and its outlook for 2017 on Friday morning, March 10, 2017, following the release of its results after market on March 9th.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s www.boviemed.com.